To evaluate the cost-effectiveness of quetiapine extended release 300 mg once daily (o.d.) in adult patients with acute bipolar depression compared with other atypical antipsychotics. METHODS: A systematic literature review was conducted to inform a mixed treatment comparison utilising a Markov Chain Monte Carlo simulation comprising of a random effects model to estimate the risk of remission, treatment-emergent mania, discontinuations, significant weight-gain ( 7%) and extrapyramidal adverse event. A weekly cycle 7-state markov model was designed to evaluate the cost-effectiveness of quetiapine extended release over a 3-year time horizon from the perspective of the UK National Health Service. A systematic literature review was completed to identify suitable health state utility values. Costs included pharmacological therapy and resource use associated with the treatment of mood events. Results were reported in cost (2009 values) per quality-adjusted life years (QALYs). A probabilistic sensitivity analysis (PSA) was conducted to assess the robustness of the results. RESULTS: The literature review only identified two other atypical antipsychotics with a sufficient quality of data to be included in the analysis, olanzapine 10 mg and aripiprazole 15 mg (In the aripiprazole trials, aripiprazole did not reach significance at 8-weeks versus placebo, the data was included for completeness). Quetiapine extended release was a cost-effective (cost: £11,568; QALYs: 2.351) treatment option dominating both olanzapine (cost: £11,584; QALYs: 2.347) and aripiprazole (cost: £11,773; QALYs: 2.328). These results were supported in the probabilistic sensitivity analysis. CONCLUSIONS: The results of this cost-utility analysis suggest that not only is quetiapine extended release effective but that it is also a cost-effective alternative versus other atypical antipsychotics in the management of adult patients with acute bipolar depression.
PMH50 CLINICAL VALIDITY OF REMISSION IN PATIENTS WITH MAJOR DEPRESSION IN POPULATION DATABASES
Sicras-Mainar A 1 , Blanca-Tamayo M 1 , Navarro-Artieda R 2 , Gutiérrez-Nicuesa L 3 , Salvatella-Pasant J 4 1 Badalona Serveis Assistencials SA, Barcelona, Spain, 2 Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain, 3 Lundbeck España SA, Barcelona, Spain, Spain, 4 Lundbeck España SA, Barcelona, Spain OBJECTIVES: To describe the concordance between remission according to clinical diagnostic orientation and remission obtained from the computerized databases of patients with major depression (MD) in a Spanish population. METHODS: Design: multicenter transversal. The assessed population was comprised by people over 17 from reformed primary care facilities, who had a MD episode between January 2003 and March 2007. A specialist in psychiatry assessed a random sample of patient histories and determined whether a certain patient was in remission according to clinical criteria. Regarding the databases, patients were considered in remission when they did not need further prescriptions of AD for at least 6 months after completing treatment for a new episode. Validity indicators (sensitivity [S] , specificity [Sp] ) and clinical utility (positive and negative probability ratio [PPR] and [NPR]) were calculated. The concordance index was established using Cohen's kappa coefficient. Significance level was p 0.05. RESULTS: 4,572 subjects were analyzed. 54.6% (CI of 95%: 53.2-56.0%) were considered in remission. Patients in remission showed lower: age (52.6 vs. 60.7), proportion of women (71.7% vs. 78.2%), general morbidity (6.2 vs. 7.7 episodes/year), RUB/year (2.7 vs. 3.0), sick leave days (31.0 vs. 38.5) and treatment duration (146.6 vs. 307.7 days); p 0.01. 133 patient histories were reviewed. The kappa coefficient was 82.8% (confidence intervals [CI] were 95%: 73.1-92.6), PPR 9.8% and NPR 0.1%. Allocation discrepancies between both criteria were found in 11 patients. S was 92.5% (CI was 95%: 88.0-96.9%) and Sp was 90.6% (CI was 95%: 85.6-95.6%), p 0.001. Reliability analysis: Cronbach's alpha: 90.6% (CI was 95%: 85.6-95.6%). CONCLUSIONS: Results show an acceptable level of concordance between remission obtained from the computerized databases and clinical criteria. The major discrepancies were found in diagnostic accuracy. and 296.5-296.9) were analyzed. Weighted, age-standardized hospitalization rates, patient demographics, and estimates of TC and LOS were assessed. RESULTS: Over the 6-year study period, 212,964 pediatric visits with a primary diagnosis of bipolar disorder were identified. Mean ( SD) age was 14.7 ( 3.4) years and 48.7% were female. Most (47.8%) were routine admissions, and the majority was covered by private insurance (51.2%). The age-standardized rate of bipolar disorder-related hospitalizations (per 10,000 2008 US pediatric population) rose slightly from 2000 to 2005, from 3.4/10,000 to 3.8/10,000, with a low of 2. 
PMH51 TRENDS IN RATES OF PEDIATRIC BIPOLAR DISORDER-RELATED HOSPITALIZATIONS AND RELATED RESOURCE USE IN THE UNITED STATES

CONCLUSIONS:
We examined trends in rates of bipolar disorder-related hospitalizations and associated outcomes among pediatric patients. We observed fairly stable rates of hospitalizations over the 6-year study period. However, LOS and TC exhibited an initial rise and subsequent decline. Health care stakeholders should be cognizant of the effect that bipolar disorder may have on hospitalizations and related resource use. Previous studies have demonstrated the ability to collect patientreported outcomes from members of an on-line patient community with chronic conditions. In this pilot study, we explore the feasibility of capturing health resource utilization data from a vulnerable population, schizophrenics. METHODS: To identify 50 subjects, we screened 369 iGuard.org members taking at least one antipsychotic: aripiprazole, clozapine, haloperidol, olanzapine, paliperidone, quetiapine, risperdone, or ziprasidone. iGuard.org is a medication monitoring service that provides drug safety information to over 1.4 million US members. Subjects completed an on-line survey regarding health resource use in the past 6 months and 2 years, among other questions. RESULTS: A total of 45 of 50 respondents (90%) identified themselves as a patient; 10% were caregivers. Most respondents ( 80%) are managed by a psychiatrist and have experienced metabolic symptoms: 68% gained 11 pounds, 14% gained 10 pounds or less, 38% were diagnosed with high cholesterol, and 10% developed diabetes. Only 16% have not experienced metabolic symptoms. With respect to resource utilization, 44% visited the ER, 24% were hospitalized, and 12% were arrested, jailed, or imprisoned in the past 6 months. Utilization within the last 2 years was as follows: 68% visited the ER, 40% were hospitalized, and 12% were arrested. Responses were inconsistent for a total of 5 of 50 patients who indicated use within the past 6 months, but not within 2 years in at least one of the three resource categories. CONCLUSIONS: The results of this study suggest that although researchers should continue to examine patient reported data for inconsistencies, patient communities can be a time and cost-efficient source of patient-reported outcomes data such as health resource utilization even for vulnerable populations.
PMH52 PATIENT-REPORTED OUTCOMES IN A VULNERABLE POPULATION: A PILOT STUDY CONDUCTED WITH A NOVEL PATIENT COMMUNITY
PMH53 PATTERNS OF HEALTH CARE RESOURCE UTILIZATION IN JAPANESE PSYCHIATRIC OUTPATIENTS: RESULTS FROM THE ONE-DAY SURVEY CONDUCTED BY THE JAPANESE ASSOCIATION OF NEURO-PSYCHIATRIC CLINICS
Inagaki A 1 , Tomita N 1 , Nishimura Y 2 , Hatou K 2 , Hirakawa H 3 1 Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, 2 Japanese Association of Mental Health Services, Shibuya-ku, Tokyo, Japan, 3 Japanese Association of Neuro-Psychiatric Clinics, Shibuya-ku, Tokyo, Japan OBJECTIVES: To identify utilization patterns of health care resources for psychosocial supports in Japanese psychiatric outpatients. METHODS: A one-day survey was conducted at 109 outpatient mental clinics from members of the Japanese Association of Neuro-Psychiatric Clinics during the period from December 10 to 16, 2008. All patients who visited the clinics on the day of survey were subjected to the study and medical staffs filled out questionnaires on patients' socio-demographic and clinical status including information about resource utilization for psychosocial supports. RESULTS: Among total 4689 patients, 42.2% were male. The mean / SD age was 47.1 17.2 years. More than two thirds of patients (37.9%) were diagnosed as mood disorders (ICD-10 F3), followed by neurotic disorders (F4: 27.7%), psychotic disorders (F2: 20.0%), organic mental disorders (F0: 2.7%) and other diagnosis (8.8%). 18.9% patients had been hospitalized at psychiatric institutions at least once. 9.8% consulted medical staffs such as psychologists and social workers, in addition to psychiatrists. 4.2% of patients utilized day/nightcare programs covered by health insurance. Utilization rate of community services including community workshops, support service for employment, local activity support center, rehabilitation service and other psychosocial resources were 2.0%, 1.3%, 0.9%, 0.2% and 1.1%, respectively. DISCUSSION: In Japan, in most cases, consultations by medical staffs are not covered by health insurance but free of charge. Meanwhile, based on "the Services and Supports for Persons with Disabilities Act", community services are provided at a cost of municipalities. Under such a circumstance, many of Japanese patients with mental disorders utilize psychosocial supports provided by local governments as well as those covered by health insurance. CONCLUSIONS: Costs for psychosocial supports borne by local governments is not included in health care cost. However, when conducting pharmacoeconomic analysis of psychotropics in Japan, it should be taken into account.
